- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Evolus Insider Sells $14,815 in Shares
Rui Avelar, an Evolus insider, sold 3,119 shares of the company's stock.
Mar. 21, 2026 at 12:42pm
Got story updates? Submit your updates here. ›
Rui Avelar, an insider at Evolus, Inc. (NASDAQ:EOLS), sold 3,119 shares of the company's stock on Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $14,815.25. Following the sale, Avelar still owns 427,423 shares in the company, valued at $2,030,259.25.
Why it matters
Insider trading activity can provide insights into a company's performance and the sentiment of its leadership. This sale by an Evolus insider may signal potential concerns about the company's outlook or could simply be part of routine portfolio management.
The details
Rui Avelar, an Evolus insider, sold 3,119 shares of the company's stock on March 20th at an average price of $4.75 per share. This transaction resulted in total proceeds of $14,815.25 for Avelar. Following the sale, Avelar still owns 427,423 shares in Evolus, valued at $2,030,259.25.
- Rui Avelar sold 3,119 shares on Friday, March 20th.
- Rui Avelar also sold 29,996 shares on Tuesday, March 17th.
- Rui Avelar sold 2,261 shares on Monday, December 22nd.
The players
Rui Avelar
An insider at Evolus, Inc. (NASDAQ:EOLS).
Evolus, Inc.
A specialty pharmaceutical company focused on medical aesthetics, headquartered in Newport Beach, California.
The takeaway
This insider sale by Rui Avelar may indicate potential concerns about Evolus' outlook, though it could also be part of routine portfolio management. Investors should continue to monitor the company's performance and any further insider trading activity.

